Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How to Withdraw a Drug: FDA’s Final Decision on Avastin

This article was originally published in RPM Report

Executive Summary

The “streamlined withdrawal” process for Avastin in metastatic breast cancer gave Genentech an extra 11 months to prepare for the transition to off-label status. It also gave FDA time to make preparations of its own.


Related Content

Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
What Will CMS Do With Avastin In Breast Cancer?
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
Genentech’s Seven Arguments For Saving Avastin: The Commissioner’s Point-By-Point Rebuttal
Roche and FDA in Oncology: Fighting in Public, Collaboarting in Private
Never Again? Why the Avastin Hearing May Be One of a Kind
Avastin and FDA/CMS Coordination: Genentech's Safe Strategy to Save Medicare Coverage
Accelerated Withdrawal in Action: The Avastin Hearing Process
The Avastin Docket: Few Comments, But Lots of Questions About Implications


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts